Circio Lists 67.7 Million Warrants on Oslo Bourse After NOK 50m Equity Raise

The latest update is out from Targovax ASA ( (GB:0RIS) ).

Circio Holding ASA has issued 67,680,945 tradable warrants on the Oslo Stock Exchange under ticker CRNAS, linked to its recent NOK 50 million rights issue and a private placement of 15,018,945 new shares. The warrants, each exercisable into one new share at 80% of the volume-weighted average share price within a set May pricing window, can be exercised between 26 May and 9 June 2026, after which any unexercised warrants will lapse.

The listing of the warrants provides existing and new investors with a leveraged way to increase their exposure to Circio ahead of key development milestones, while also setting up a potential second wave of equity funding if the instruments are exercised. However, shareholders who do not take up their warrant rights face dilution of their stakes, underscoring the capital-intensive nature of Circio’s strategy to advance its circRNA platform and legacy immuno-oncology program.

More about Targovax ASA

Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform is designed to enhance RNA stability and protein expression for use in genetic medicine, cell therapy and chronic disease, while its TG01 peptide vaccine targets RAS-mutated cancers in ongoing trials in Norway and the U.S.

YTD Price Performance: 15.35%

Average Trading Volume: 4,294,833

Current Market Cap: NOK251.7M

For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.